01:07 PM EST - Biovail Corp. : reversed a year-ago loss in the third quarter but posted a sharp drop in revenues amid increased generic competition for its Wellbutrin XL antidepressant. The Toronto-based company said revenues fell to $188.9 million from $282.3 million a year earlier, as Wellbutrin sales decreased to $53.5 million from $123.3 million. Biovail Corp.
shares T.BVF are trading down 28 cents at $17.17.
